Compare GLAD & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLAD | ZURA |
|---|---|---|
| Founded | 2001 | 2022 |
| Country | United States | United States |
| Employees | 65 | 30 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.7M | 435.0M |
| IPO Year | N/A | N/A |
| Metric | GLAD | ZURA |
|---|---|---|
| Price | $18.18 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $22.33 | $11.78 |
| AVG Volume (30 Days) | 215.3K | ★ 482.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | $11.70 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $0.99 |
| 52 Week High | $29.50 | $7.19 |
| Indicator | GLAD | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 60.94 |
| Support Level | N/A | $5.62 |
| Resistance Level | $21.54 | N/A |
| Average True Range (ATR) | 0.47 | 0.50 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 25.46 | 80.14 |
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.